NCT04691141 (HATCH) is a Phase 1, PHASE2 clinical trial of ATG-016 in Myelodysplastic Syndrome, sponsored by Shanghai Antengene Corporation Limited.

Who is sponsoring NCT04691141?

NCT04691141 is sponsored by Shanghai Antengene Corporation Limited.

What drugs are being tested in NCT04691141?

Interventions in NCT04691141: ATG-016.

What condition does NCT04691141 study?

NCT04691141 studies Myelodysplastic Syndrome.

Is NCT04691141 still recruiting?

NCT04691141 is currently terminated. Last updated 17 April 2024.

Last reviewed 2024-04-17 · How we verify

NCT04691141: HATCH

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Evaluating the Pharmacokinetics, Safety, and Efficacy of ATG 016 Monotherapy in IPSS-R Intermediate Risk and Above Myelodysplastic Syndrome (MDS)

Terminated Phase 1, PHASE2 Last updated 17 April 2024

What this trial tests

Phase 1, PHASE2 trial testing ATG-016 in Myelodysplastic Syndrome in 15 participants. Terminated before completion.

Timeline

23 February 2021

Primary endpoint
19 September 2023

19 September 2023

Quick facts

Lead sponsor	Shanghai Antengene Corporation Limited
Phase	Phase 1, PHASE2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	15
Start date	23 February 2021
Primary completion	19 September 2023
Estimated completion	19 September 2023
Sites	6 locations across China

Drugs / interventions tested

ATG-016 — full drug profile →

Conditions studied

Myelodysplastic Syndrome — all drugs for Myelodysplastic Syndrome →

Sponsor

Shanghai Antengene Corporation Limited — full company profile →

Who can join

18 and older, any sex, with Myelodysplastic Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a Phase Ⅰ/II, Open-label Study to Investigate the Pharmacokinetics, Safety, and Efficacyof ATG 016 Monotherapy in IPSS-R Intermediate Risk and above Myelodysplastic Syndrome (MDS) Patients after Failure of Hypomethylating Agent (HMA)-based Therapy.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Risk-Adapted, Individualized Treatment Strategies of Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML).
Bewersdorf JP, Zeidan AM. · · 2021 · cited 21× · PMID 33807279 · DOI 10.3390/cancers13071610

Verify or expand the search:

Other trials of ATG-016

Trials testing the same drug.

NCT05010525 — A Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of ATG 016 Monotherapy in Patients With Advance · Phase 1, PHASE2 · terminated

Other recruiting trials for Myelodysplastic Syndrome

Currently open trials in the same condition.

NCT07020533 — A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Pa · Phase 1 · recruiting
NCT07422480 — A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myel · Phase 3 · recruiting
NCT07107126 — Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes · Phase 1 · recruiting
NCT06781099 — Feasibility Trial of Extracorporeal Iron Purification in Patients With Myelodysplastic Syndrome or Myelofibrosis · NA · recruiting
NCT07285044 — The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Tr · Phase 2 · recruiting

Other Shanghai Antengene Corporation Limited trials

Trials by the same sponsor.

NCT05010525 — A Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of ATG 016 Monotherapy in Patients With Advance · Phase 1, PHASE2 · terminated
NCT04518137 — A Study of Evaluating the Safety and Efficacy of ATG-008 for Advanced Solid Tumors (BUNCH) · Phase 2 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04691141 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai Antengene Corporation Limited
Last refreshed: 17 April 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04691141.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing